EGFR and non-small cell lung carcinoma: Currently, several epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) that have been approved by the Food and Drug Administration and National Medical Products Administration are widely used in treating patients with advanced NSCLC with EGFR-mutations.